407 related articles for article (PubMed ID: 27626446)
1. Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.
Derman Y; Selby K; Miethe S; Frenzel A; Liu Y; Rasetti-Escargueil C; Avril A; Pelat T; Urbain R; Fontayne A; Thullier P; Sesardic D; Lindström M; Hust M; Korkeala H
Toxins (Basel); 2016 Sep; 8(9):. PubMed ID: 27626446
[TBL] [Abstract][Full Text] [Related]
2. Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.
Miethe S; Rasetti-Escargueil C; Avril A; Liu Y; Chahboun S; Korkeala H; Mazuet C; Popoff MR; Pelat T; Thullier P; Sesardic D; Hust M
PLoS One; 2015; 10(10):e0139905. PubMed ID: 26440796
[TBL] [Abstract][Full Text] [Related]
3. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.
Rasetti-Escargueil C; Avril A; Chahboun S; Tierney R; Bak N; Miethe S; Mazuet C; Popoff MR; Thullier P; Hust M; Pelat T; Sesardic D
MAbs; 2015; 7(6):1161-77. PubMed ID: 26381852
[TBL] [Abstract][Full Text] [Related]
4. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
5. Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.
Miethe S; Mazuet C; Liu Y; Tierney R; Rasetti-Escargueil C; Avril A; Frenzel A; Thullier P; Pelat T; Urbain R; Fontayne A; Sesardic D; Hust M; Popoff MR
PLoS One; 2016; 11(8):e0161446. PubMed ID: 27560688
[TBL] [Abstract][Full Text] [Related]
6. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.
Miethe S; Rasetti-Escargueil C; Liu Y; Chahboun S; Pelat T; Avril A; Frenzel A; Schirrmann T; Thullier P; Sesardic D; Hust M
MAbs; 2014; 6(2):446-59. PubMed ID: 24492304
[TBL] [Abstract][Full Text] [Related]
7. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
8. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
9. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.
Matsumura T; Amatsu S; Misaki R; Yutani M; Du A; Kohda T; Fujiyama K; Ikuta K; Fujinaga Y
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32392791
[TBL] [Abstract][Full Text] [Related]
10. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
Tremblay JM; Vazquez-Cintron E; Lam KH; Mukherjee J; Bedenice D; Ondeck CA; Conroy MT; Bodt SML; Winner BM; Webb RP; Ichtchenko K; Jin R; McNutt PM; Shoemaker CB
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987745
[TBL] [Abstract][Full Text] [Related]
11. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.
Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR
Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
[TBL] [Abstract][Full Text] [Related]
13. Production and characterization of a neutralizing antibody against botulinum neurotoxin A.
Xiong X; Lv S; Fu C; Li L; Sun Z; Han X; Zhang W
J Immunol Methods; 2020 Dec; 487():112871. PubMed ID: 33007319
[TBL] [Abstract][Full Text] [Related]
14. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.
Avril A; Miethe S; Popoff MR; Mazuet C; Chahboun S; Rasetti-Escargueil C; Sesardic D; Thullier P; Hust M; Pelat T
BMC Biotechnol; 2015 Sep; 15():86. PubMed ID: 26382731
[TBL] [Abstract][Full Text] [Related]
15. Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Jpn J Infect Dis; 2013; 66(1):46-50. PubMed ID: 23429085
[TBL] [Abstract][Full Text] [Related]
16. Strategies to design inhibitors of Clostridium botulinum neurotoxins.
Cai S; Singh BR
Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211
[TBL] [Abstract][Full Text] [Related]
17. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
18. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
Barash JR; Arnon SS
J Infect Dis; 2014 Jan; 209(2):183-91. PubMed ID: 24106296
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model.
Tomic MT; Farr-Jones S; Syar ES; Niemuth N; Kobs D; Hackett MJ; Espinoza Y; Martinez Z; Pham K; Snow DM; Marks JD; Cobb RR
Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564675
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
